1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Mental Health Market Trends
  5. > CNS Drug News 17 NOVEMBER 2014

CNS Drug News 17 NOVEMBER 2014

  • November 2014
  • -
  • Espicom Business Intelligence
  • -
  • 24 pages

Industry Trend Analysis - FDA Approval Will See Lemtrada Become A Blockbuster
Industry Brief - Impax Submits MAA For IPX066
Industry Brief - NeuroDerm Reports Positive Top-Line Phase II Results In Moderate-To-Severe PD
Industry Brief - Anavex Receives Regulatory Approval To Initiate Phase IIa Trial In AD
Industry Brief - GliaCure's AD Product Candidate Receives FDA Fast Track Designation
Industry Brief - FDA Grants ODD To Auspex' SD-809 For HD
Industry Brief - MTP Files Application For Additional Indication Of Radicut In ALS
Industry Brief - D-Pharm Reports First Results From THR-18 Phase II Study In tPA-Treated AIS Patients
Industry Brief - FDA Approves sNDAs For Invega Sustenna For Schizoaffective Disorder
Industry Brief - FDA Accepts Actavis' Saphris sNDA For BPID In Paediatric Patients
Industry Brief - Breckenridge Reports Quetiapine Approval In US
Industry Brief - Highland Reports Positive Top-Line Data From Phase III Trial In Paediatric ADHD
Industry Brief - Transition Reports Findings From BPD Phase II Study
Industry Brief - Pain Therapeutics To Regain Full Rights To Remoxy From Pfizer
Industry Trend Analysis - Avanir's Inhaled Migraine Therapy Will Not Be FDA-Approved In November
Industry Brief - Pernix Submits sNDA For Treximet Use In Adolescent Patients
Industry Brief - Ono To Not File Remimazolam In Japan; To Return Rights To PAION
Industry Trend Analysis - Smoking Cessation: A Blockbuster Opportunity For Belviq
Industry Trend Analysis - Eisai's Fycompa Will Remain Off German Market
Industry Brief - Fourth US Patent Protecting Trokendi XR Issued
Industry Brief - Eisai's Zonegran Approved In Russia For Children/Adolescents
Industry Brief - Fycompa Receives Reimbursement In Australia
Industry Brief - SAGE Reports Positive Top-Line Phase II Data In SRSE
Industry Brief - NeuroSearch Signs Agreement To Transfer Phase I-II Projects
Industry Brief - ICT/Takeda To Terminate Collaboration On PDE1 Inhibitors For CNS Disorders
Industry Trend Analysis - Neuren Targets Growing Orphan Drug Market
Industry Brief - Eisai Neuroscience Business Officially Launched In Belgium And Luxembourg
Industry Brief - CNS Conferences - February 2015

Table Of Contents

CNS Drug News 17 NOVEMBER 2014

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers
Neurological Disorder Drugs Market - Europe Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

Neurological Disorder Drugs Market - Europe Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

  • $ 5795
  • Industry report
  • December 2016
  • by Transparency Market Research

Europe Neurological Disorder Drugs Market: Overview This report on the neurological disorder drugs market studies the current as well as future prospects of the market in Europe. Health concern related ...

Epiomic Epidemiology Series: Lewy Body Dementia Forecast in 12 Major Markets 2017-2027

Epiomic Epidemiology Series: Lewy Body Dementia Forecast in 12 Major Markets 2017-2027

  • $ 5112
  • Industry report
  • February 2017
  • by Black Swan Analysis Ltd

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Lewy Body Dementia in 12 Major Markets Dementia with Lewy Bodies (DLB) is the second most frequent cause of age related neurodegenerative ...

Epiomic Epidemiology Series: Alzheimer%s Disease Forecast in 12 Major Markets 2017-2027

Epiomic Epidemiology Series: Alzheimer%s Disease Forecast in 12 Major Markets 2017-2027

  • $ 5112
  • Industry report
  • February 2017
  • by Black Swan Analysis Ltd

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Alzheimer’s disease in 12 Major Markets Alzheimer's disease (AD) is a progressive, irreversible neurodegenerative disorder. It is ...


ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.